Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.
IDH1 inhibitor delayed progression of this often aggressive cancer of the bile ducts.
Nine grants will enable researchers to study CBD and other components of marijuana.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.
Late-stage cancers identified through emergency department visits may reflect a lack of access to primary care and screening.
People who paid more money out-of-pocket filled fewer prescriptions and had shorter overall survival.
Efforts to control viral hepatitis are falling behind, in part because of the growing opioid epidemic and homelessness crisis.
AACR report highlights progress in preventing and treating cancer—including 27 new drug approvals last year—but disparities persist.
Two androgen receptor inhibitors improved survival by 33% in men with metastatic prostate cancer that responds to hormone therapy.
The Affordable Care Act erases racial disparities in care for advanced cancers.
First KRAS targeted therapy shows promise for lung and colon cancer
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
The test was able to identify many cancers, and their location, at early stages.
Widespread vaccination could potentially eliminate cervical, anal, oral and other HPV-related cancers.
FDA approves Rozlytrek for cancers with certain gene mutations
The cancer is particularly difficult to treat with traditional therapies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.